Insight

Biagio Ricciuti: 5-year update from the NADIM trial

Biagio Ricciuti/X

Oct 16, 2024, 17:00

Biagio Ricciuti: 5-year update from the NADIM trial

Biagio Ricciuti shared a post on X about a recent paper by Mariano Provencio et al. published in The Lancet Oncology.

“5-year update from the NADIM trial (perioperative CT and nivo in stage III NSCLC)

5-year PFS 65% OS 69.3%
pCR: PFS 92% and OS 95.8%
Non-pCR: PFS 60% and OS 66%
2 patients with pCR had disease progression and had mutations in KEAP1 and EGFR.”

“Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial”

Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, Atocha Romero, Alberto Cruz-Bermúdez et al.

Biagio Ricciuti: 5-year update from the NADIM trial

More posts featuring Biagio Ricciuti.

Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.

Alberto Cruz-Bermúdez. Amelia Insa Atocha Romero Biagio Ricciuti cancer Dana-Farber Cancer Institute Ernest Nadal Mariano Provencio NADIM trial nivolumab NSCLC OncoDaily Oncology The Lancet Oncology

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage